title: Autoantibodies to ganglionic acetylcholine receptors in autoimmune autonomic neuropathies.
abstract: BACKGROUND
  Idiopathic autonomic neuropathy is a severe, subacute disorder with a presumed autoimmune basis. It is indistinguishable from the subacute autonomic neuropathy that may accompany lung cancer or other tumors. Autoantibodies specific for nicotinic acetylcholine receptors in the autonomic ganglia are potentially pathogenic and may serve as serologic markers of various forms of autoimmune autonomic neuropathy.
  
  
  METHODS
  We tested serum from 157 patients with a variety of types of dysautonomia. Immunoprecipitation assays with iodine-125-labeled epibatidine and solubilized human neuroblastoma acetylcholine receptors were used to detect autoantibodies that bound to or blocked ganglionic receptors.
  
  
  RESULTS
  Ganglionic-receptor-binding antibodies were found in 19 of 46 patients with idiopathic or paraneoplastic autonomic neuropathy (41 percent), in 6 of 67 patients with postural tachycardia syndrome, idiopathic gastrointestinal dysmotility, or diabetic autonomic neuropathy (9 percent), and in none of 44 patients with other autonomic disorders. High levels of the binding antibodies correlated with more severe autonomic dysfunction (including the presence of tonic pupils). Levels of these antibodies decreased in patients who had clinical improvement. All seven patients with ganglionic-receptor-blocking antibodies had ganglionic-receptor-binding antibodies and had idiopathic or paraneoplastic autonomic neuropathy.
  
  
  CONCLUSIONS
  Seropositivity for antibodies that bind to or block ganglionic acetylcholine receptors identifies patients with various forms of autoimmune autonomic neuropathy and distinguishes these disorders from other types of dysautonomia. The positive correlation between high levels of ganglionic-receptor antibodies and the severity of autonomic dysfunction suggests that the antibodies have a pathogenic role in these types of neuropathy.
authors.affiliation: Department of Neurology, Mayo Clinic, Rochester, Minn 55905, USA. verns@mayo.edu
authors.forename: S
authors.initials: S
authors.lastname: Vernino
authors.forename: P A
authors.initials: PA
authors.lastname: Low
authors.forename: R D
authors.initials: RD
authors.lastname: Fealey
authors.forename: J D
authors.initials: JD
authors.lastname: Stewart
authors.forename: G
authors.initials: G
authors.lastname: Farrugia
authors.forename: V A
authors.initials: VA
authors.lastname: Lennon
mesh_terms: D000328:Adult; D000368:Aged; D001323:Autoantibodies / Q000097:blood*; D001327:Autoimmune Diseases / Q000276:immunology*; D001342:Autonomic Nervous System Diseases / Q000145:classification / Q000276:immunology* / Q000503:physiopathology; D003929:Diabetic Neuropathies / Q000276:immunology; D005260:Female; D005500:Follow-Up Studies; D005725:Ganglia, Autonomic / Q000276:immunology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D020361:Paraneoplastic Syndromes, Nervous System / Q000276:immunology; D011978:Receptors, Nicotinic / Q000276:immunology*; D012680:Sensitivity and Specificity; D012720:Severity of Illness Index; D013546:Sweating
chemical_list: D001323:Autoantibodies; D011978:Receptors, Nicotinic